European Molecular Tumor Board
Information about the SIOPEN European Molecular Tumor Board (EMTB)
While clinical tumor conferences often lack experts in molecular biology and bioinformatics, molecular tumor conferences have a strong focus on the interpretation of molecular data, but lack a comprehensive clinical view of the patient and the specific tumor entity.
With the SIOPEN European Molecular Tumor Board (“SIOPEN EMTB”) we aim to combine all expertise to provide a rational recommendation for the therapy of a given neuroblastoma patient, taking both, the specific clinical course as well as the molecular data, into account. This approach is likely to provide the best solution for the individual patient. The team includes experts in bioinformatics, biology, immunology, radiology, nuclear medicine, stem cell transplantation, surgery, radiotherapy and pediatric oncology, all with specific expertise in the field of neuroblastoma.
The SIOPEN EMTB is independent of any molecular data analysis platform, but can also assist in planning, initiating and performing appropriate molecular analyses for any patient. The format of the EMTB will be a web-based conference (dial-in see below), that will be conducted every first Thursday each month from 5.00 -6.00 p.m. starting November 8st 2018 (as Nov 1st is a holiday in Germany).
The typical patient to be presented at the SIOPEN EMTB is a patient with a relapsed or refractory neuroblastoma, for whom a salvage therapy is being planned. However, any patient at any point of therapy may be presented.
To register a patient to be discussed within the SIOPEN EMTB, please complete the registration form and sent it via email to email@example.com or via Fax to +49 30 450 566906 at least three days prior to the next SIOPEN EMTB. Please note that the national PI should be informed about a patient registered. Submission of original data of molecular analysis, relevant images and previous recommendations of molecular tumor boards is appreciated, but not mandatory. Please attach any accompanying data or sent it in on CD or USB Stick to Angelika Eggert (Postal Address: Prof. Dr. Angelika Eggert, Klinik für Pädiatrie m.S. Onkologie und Hämatologie, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin). A protected server for uploading data as well as radiologic images will be set up in the next weeks.
Treating physicians of any patient to be discussed are invited to dial in and are requested to give a brief overview of the patient’s clinical course. For each discussed patient, a written recommendation from the SIOPEN ETMB will be provided within four workdays.
The SIOPEN EMTB will be conducted using Skype Business. Physicians who present patients, as well as regular members of the SIOPEN EMTB will be invited via email (that contains all free dial-in information) the day before the SIOPEN EMTB. Free dial-in without invitation will be possible if you have installed Skype Business, or via a web app (cave: you need administrator rights to execute the skype business web app).